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Abstract: 
 
Introduction: 
 
Optic Pathway/Hypothalamic Gliomas (OPHGs) are generally benign but situated in an 
exquisitely sensitive brain region. They follow an unpredictable course and are usually 
impossible to completely resect. We present a case-series of 10 patients who underwent 
surgery for OPHGs with the aid of intra-operative MRI (ioMRI). The impact of ioMRI 
on OPHG resection is presented and a role for ioMRI in partial resection is discussed. 
 
Methods: 
 
10 patients with OPHGs managed surgically utilising ioMRI at Alder Hey Children’s 
Hospital between 2010 and 2013 were retrospectively identified. Demographic and 
relevant clinical data were obtained.  
  
MRI was used to estimate tumour volume pre-operatively and post-resection. If ioMRI 
demonstrated that further resection was possible, second look surgery, at the discretion 
of the operating surgeon was performed, followed by post-operative imaging to 
establish the final status of resection. Tumour volume was estimated for each MR image 
using the MRIcron software package. 
 
Results: 
 
Control of tumour progression was achieved in all patients. 7 patients had on table, 
second look surgery with significant further tumour resection following ioMRI without 
any surgically related mortality or morbidity. The median additional quantity of tumour 
removed following second look surgery, as a percentage of the initial total volume was 
27.79% (range 11.2-59.2%). The final tumour volume remaining with second look 
surgery was 23.96% vs. 33.21% without (p=0.1). 
 
Conclusions: 
 
OPHGs are technically difficulty to resect due to their eloquent location, making them 
suitable for debulking resection only. IoMRI allows surgical goals to be reassessed 
intra-operatively following primary resection. Second look surgery can be performed if 
possible and necessary and allows significant quantities of extra tumour to be resected 
safely. Although the clinical significance of additional tumour resection is not yet clear, 
we suggest that ioMRI is a safe and useful additional tool, to be combined with 
advanced neuronavigation techniques for partial tumour resection.  
 
 
 
 
 
 
 
 
 
 
 
 
Introduction: 
 
Optic pathway/hypothalamic gliomas (OPHG) account for approximately 2-7% of 
intracranial tumours in the paediatric population, with 65% of these tumours found in 
children less than 5 years of age [2,11,16,24,28,33]. They comprise a broad spectrum of 
tumour sizes and localisations, and typically follow an unpredictable course. 
Presentation tends to be due to compression of the optic pathways and diencephalon, 
but obstructive hydrocephalus is also a common feature [2,24]. Histologically, OPHGs 
are nearly always low-grade tumours, with pilocystic astrocytomas (WHO grade I) 
accounting for the majority, along with a proportion of pilomyxoid astrocytomas (WHO 
grade II) [5,7,9,11,17,22,30]. A strong association with Neurofibromatosis Type 1 
(NF1) is observed, which tends to correlate with a more benign course 
[6,10,11,13,17,24-25,28,34]. 
 
The management of OPHGs has been the topic of much debate. The role of surgery has 
traditionally been less favourable when compared to radiotherapy and chemotherapy 
due to the relatively benign nature of these tumours, their eloquent location to the visual 
pathways, and the impossibility of obtaining a complete resection. A recently published 
multidisciplinary consensus statement regarding surgery for these lesions stated “It was 
agreed that primary attempted surgical resection of HCLGG [hypothalamic chiasmatic 
low-grade glioma] is not the current recommended standard of care. However, it was 
acknowledged that selected cases were amenable to attempted resection or debulking 
with low risk” [35]. We have previously demonstrated that good functional outcomes 
and long-term survival can be achieved in children with OPHGs by using a tailored 
therapeutic approach that includes chemotherapy, radiotherapy, and surgery in selected 
cases. We believe that surgery has a clear role for diagnosis, tumour control, and relief 
of mass effect, and is safe and effective without adjuvant therapy [12]. By limiting 
radiotherapy use to older children in whom other therapies have failed, the well-
described, devastating complications of midline cranial irradiation can be avoided [12].  
 
Incorporating ioMRI with neuronavigation for tumour resection in the adult population 
has been shown to have a synergistic effect on resection because ioMRI allows the 
neuronavigation system to be updated intra-operatively, counteracting brainshift and 
allowing the surgical aim to be modified accordingly to safety considerations or new 
surgical goals [19,23,27,29]. There is limited evidence for the use of ioMRI in the 
paediatric population, and we have previously demonstrated that ioMRI has increased 
the rate of complete resections, with intraoperative surgical strategy being modified in 
30% of procedures in our series of 40 cranial tumours [3,4,37]. Other groups have also 
demonstrated a modified surgical strategy ranging from 21% to 60% [8,14,20-21,27]. 
Although the clinical effectiveness of ioMRI has been demonstrated for total tumour 
resection [4,31], a role for ioMRI has yet to be demonstrated in partial and subtotal 
tumour resection. 
 
In the present paper, we seek to add to the discussion about the role of ioMRI in partial 
and subtotal resection of OPHG tumours. As the goal of surgery in patients with OPHG 
tumours is inevitably debulking resection, these patients represent a suitable cohort by 
which to evaluate the role of ioMRI. We describe a series of 10 patients with Optic 
Pathway/Hypothalamic Gliomas, in which the initial tailored surgical aim was partial or 
subtotal resection with the aid of ioMRI and image analysis with MRIcron.38 We 
describe the medical and surgical management of these patients together with their 
outcome and discuss the implications for this strategy on tumour resection. Within this 
series the major surgical interventions were performed by a single surgeon (C.M). 
 
 
Methods: 
 
Patient selection: 
 
We identified all patients with OPHG tumours managed surgically with ioMRI at our 
centre between 2010 and 2013. 11 patients were initially identified. One patient was 
subsequently excluded as the aim of this patient’s surgery was deemed to be total, rather 
than subtotal. This patient had an optic pathway Glioma that had caused an irreversible 
loss of vision. As preservation of the optic nerve to spare vision was futile, subtotal 
resection was not the surgical intent. 
 
Data collection: 
 
Medical records and relevant MR imaging was obtained for each patient. Demographics 
including sex and age at presentation were noted. Previous chemotherapy and 
radiotherapy history was recorded along with NF1 status. Tissue diagnosis, anatomical 
location, pre-operative endocrine dysfunction, and presenting symptoms were recorded. 
Operative approach +/- second look surgery, postoperative endocrine and hypothalamic 
dysfunction, and time to follow-up were also recorded.  
 
Surgery & Imaging: 
 
Pre-operative MRI included T1-weighted 1-mm isotropic 3-D gradient-echo with and/or 
without gadolinium, which provided the volumetric data for neuronavigation. Brainlab 
neuronavigation was used to perform MRI image fusion during surgery. All patients had 
an early limited ioMRI scan following maximal resection, as determined by the 
operating surgeon. In patients whose first ioMRI indicated that further resection was 
possible, neuronavigation was updated with the new T1 non-contrast volumetric data 
prior to further resection. The early scan was particularly useful thus to re-establish 
accurate and safe navigation after initial debulk and to evaluate in particular the extent 
of resection in terms of avoiding the floor of the third ventricle and hypothalamus. 
Following second look surgery; a new ioMRI was obtained to establish the final status 
of resection, and the satisfactory completion of the operation. The full ioMRI protocol 
has been discussed in our previous publication [1].  
 
In the 3 patients where no further surgery was performed – the extent of the resection 
was already felt to be adequate and to have achieved the pre-operative goal and/or it 
was felt that further resection could damage the vital hypothalamic/optic pathway 
structures. 
 
The surgical approach used was transcallosal in 7 patients, while 1 patient had a 
combined transcallosal and pterional approach, 1 had a cerebellopontine angle approach, 
and 1 had a pterional approach. 
 
 
Semi-automated Delineation of Tumour Tissue: 
In order to estimate the percentage of brain tumour resected between each MR image 
acquisition it was necessary to segment the tumour on each MR image. These regions 
were obtained using the software MRIcron [38]. The semi-automated process was 
iterative, involving two main steps, namely seeded 3D region-growing followed by 3D 
Gaussian smoothing. 
 
In region-growing a seed is manually placed at approximately the centre of mass of the 
tumour. A recursive process is then performed where neighbouring voxels which (a) are 
no further away from the seed voxel than “Radius (mm)”, (b) have grey-level no more 
than “Difference from origin” different to the grey-level of the seed voxel and (c) have 
grey-level no more than “Difference at edge” different to the grey-levels of its 
neighbours are included in the region. 
Due to the high contrast between grey-level intensity of tumour tissue and cystic areas 
within the tumour, voxels representing cystic fluid are not included by the region-
growing. Several regions were therefore created to encompass the entire tumour and 
these were then consolidated into a single large region. 
 
Using MRIcron, the regions were then smoothed in order to in-fill gaps and blur any 
rough edges. This technique makes use of two parameters, namely the “FWHM (mm)” 
and the “Threshold”. [38] The first parameter, the full width half maximum, alters the 
width of the smoothing function. The second parameter determines the intensity 
threshold for including voxels into the region. This threshold was left constant for the 
entire dataset. Although the smoothing technique correctly discards groups of voxels 
that fall outside the tumour and in-fills gaps within the tumour, it also results in the 
deletion of voxels on the boundary of the region. It was therefore required to perform 
region growing and smoothing iteratively until a satisfactory result was achieved.  
 
The regions were then reviewed and found to be sufficiently accurate by an expert 
neuroradiologist with experience in ioMRI interpretation. Tumour volumes were then 
independently calculated on pre and intra operative images and postoperative images 
when second look surgery had been performed with the stage of resection blinded to the 
operator. Student T test was used to compare the final resection status between groups. 
This study was approved by the research department of our institution as a service 
evaluation, as defined by the United Kingdom National Patients Safety Agency. 
 
 
 
 
 
 
 
Results: 
 
A total of 10 patients (5 males, 5 females) with OPHGs undergoing surgical 
management at our centre with the aid of ioMRI were included in this series. 1 patient 
who underwent surgery with the aim of total resection due to existing damage to the 
optic pathways was excluded as previously described. Demographic and clinical data 
for all patients is summarised below (Table 1). 
 
Average follow-up was 28 months (range 1-40). All patients were alive at follow-up 
without any surgically related morbidity. 
 
1 patient was investigated due to an underlying diagnosis of NF1 (the only case in this 
series). 3 patients already had hypothalamic/pituitary deficits pre-op (including 1 with 
diabetes insipidus). 
 
8 patients had a tissue diagnosis of pilocytic astrocytoma. 1 patient had a diagnosis of 
pilomyxoid astrocytoma. 1 patient had a high grade glioma. 
 
Treatment history: 
 
5 patients had surgery as their first mode of treatment at our centre. 3 of these patients 
ultimately received post-operative chemotherapy due to tumour progression and have 
remained stable since. In the remaining patients the tumour size remained stable at 
follow up. 5 ‘salvage’ patients had received variable degrees of treatment at another 
centre and were subsequently referred to our centre for further management. All 5 
patients had received at least one course of chemotherapy, with 4 having received 
radiotherapy in addition to chemotherapy. All 5 patients had received previous surgery 
for biopsy, debulking, or hydrocephalus management. Despite all of the previous 
treatments they continued to progress and thus were referred for further surgery. 
 
Complications: 
 
There were no neurological complications and no new neurological deficits recorded 
after surgery.  
 
Postoperative endocrine and hypothalamic dysfunction and follow-up: 
 
4 patients developed new transitory diabetes insipidus post operatively, however all 
resolved with no new permanent cases of DI.  
 
Vision 
 
4 patients initially presented with a disturbance in their vision. Post operatively, there 
were no cases of new visual deficits at follow-up although surgery resulted in no 
improvement either.  
 
Surgical outcome: 
 
7 patients underwent second look surgery and further tumour resection following ioMRI 
where the operating surgeon was able to safely establish new operative goals. Imaging 
of a typical case is illustrated with MRI images of patient 7 including pre, intra, and 
post-op (Figure 1). 
 
Resection volumes: 
 
Resection volumes for first look surgery (n=10), second look surgery (n=7), and 
remaining tumour volume, as a percentage of the original tumour volume are 
summarised graphically (Figure 2). 
 
The median additional quantity of tumour removed following second look surgery, as a 
percentage of the initial total volume was 27.79% (range 11.2-59.2%). The final tumour 
volume remaining with second look surgery (n=7) was 23.96% vs. 33.21% without 
(n=3) (p=0.1) (Figure 3). 
 
 
	  
Figure	  1	  –	  MRI	  images	  of	  an	  illustrative	  case	  (Patient	  8).	  A	  –	  Pre-­‐op	  T1	  Sag	  with	  Gad	  and	  B	  –	  Pre-­‐op	  T1	  Coronal	  with	  Gad,	  
demonstrating	  a	  mainly	  posterior	  exophytic	  hypothalamic/third	  ventricle	  glioma.	  C	  –	  Intra-­‐op	  T1	  Sag	  without	  Gad	  and	  D	  –	  Intra-­‐op	  
T1	  Coronal	  without	  Gad,	  surgeon	  felt	  it	  was	  possible	  to	  remove	  more	  of	  the	  posterior	  tumour	  and	  navigation	  was	  updated.	  E	  –	  
Post-­‐op	  T1	  Sag	  with	  Gad	  and	  F	  –	  Post-­‐op	  T1	  Coronal	  with	  Gad,	  final	  intra-­‐operative	  MR	  images.	  Surgeon	  satisfied	  with	  maximal	  
safe	  debulk.	  A	  thin	  layer	  of	  tumour	  has	  been	  left	  safely	  on	  the	  floor	  of	  the	  third	  ventricle	  and	  chiasm.	  Images	  demonstrate	  the	  
transcallosal	  interforniceal	  route	  that	  was	  taken	  in	  this	  case.	  No	  new	  deficits	  post-­‐operatively.	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  Figure	   2	   –	   Tumour	   resection	   volumes	   expressed	  as	   a	   percentage	  of	   the	   total	   tumour	   volume	   for	   all	   10	   patients.	   Raw	  data	  was	  
generated	   from	   the	  MRIcron	   software	   package.	  Where	   only	   one	   phase	   of	   resection	   has	   been	   performed,	   one	   bar	   is	   shown	   to	  
represent	  the	  resection	  volume,	  followed	  by	  a	  second	  bar	  to	  represent	  the	  remaining	  tumour	  volume	  (Patients	  1-­‐3).	  Where	  second	  
look	  surgery	  has	  been	  performed,	  following	  iMRI,	  the	  first	  bar	  represents	  the	  initial	  resection	  volume;	  the	  second	  bar	  represents	  the	  
second	  look	  surgery	  resection	  volume,	  while	  the	  final	  bar	  represents	  the	  remaining	  tumour	  volume	  (Patients	  4-­‐10).	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No. Sex Age Presentation 
Pre-Op 
Endocrine 
Disturbance 
Surgical 
approach 
2nd 
look Histology Nf1 
New Post-
Op 
Endocrine 
Disturbance 
New Post-Op 
Hypothalamic 
Disturbance 
Treatment 
Naive 
Radio 
Tx 
Chemo 
Tx 
F/U 
(Months) 
 
1 F 6Y 
Brainstem 
compression 
Visual 
deterioration 
Ataxia 
 
Pan-hypo 
CP Angle No PA No DI (transitory) None No + + 
40 
2 F 2Y Hydrocephalus None Pterional No PA No None None Yes - + 
22 
3 F 8Y 
Visual loss 
Hydrocephalus 
ACTH 
deficit Transcallosal No PA No 
DI 
(transitory) None No + + 
40 
4 M 3M 
Macrocephaly 
Seizures 
Hydrocephalus 
None Transcallosal Yes HGG No DI (transitory) None Yes - + 
39 
5 M 15Y Bi-temporal hemianopia None 
Transcallosal 
+ Pterional Yes PA No None None Yes - - 
36 
6 M 5Y 
Left eye visual 
loss 
Hydrocephalus 
None Transcallosal Yes PA No DI (transitory) None No + + 
40 
7 F 10Y 
Squint, 
Hydrocephalus 
None Transcallosal Yes PMIX No None None Yes - + 
24 
8 M 8Y Ix of NF1 
DI 
Precocious 
puberty 
Transcallosal Yes PA Yes None None No - + 
31 
9 F 9Y 
Growth delay 
Hydrocephalus 
DI 
SIADH 
 
Transcallosal Yes PA No None None No + + 
5 
10 M 2Y Hydrocephalus None Transcallosal Yes PA No None None Yes - - 
1 
 
Table 1 
 
Discussion: 
 
High-field strength ioMRI in combination with state-of-the-art neuronavigation is 
becoming increasingly popular as a tool to facilitate the resection of both adult and 
paediatric brain tumours. The benefits of being able to reassess surgical goals, and 
update neuronavigation, thereby counteracting brainshift potentially allows for more 
accurate and more efficacious tumour resection in both adults and children 
[1,3,4,14,19,20,21,23,26,27,29]. 
 
The surgical management of OPHGs has historically caused much debate because the 
tumours themselves are low grade and tend to follow a benign course, are located in an 
eloquent area, and are near impossible to completely resect. Therefore, chemotherapy 
and radiotherapy have traditionally provided the primary management options. A large 
proportion of these tumours occur in children under the age of 5 years and the use of 
midline cranial radiotherapy below this age has well-described, devastating effects [12]. 
However, surgery is neither curative nor completely free of risk considering the 
eloquent location of these tumours to the optic pathways and diencephalon, and the risk 
of causing new, or worsening existing endocrine and/or hypothalamic disturbances. 
 
However, a multidisciplinary consensus statement on the management of these tumours 
stated “It was agreed that primary attempted surgical resection of HCLGG 
[hypothalamic chiasmatic low-grade glioma] is not the current recommended standard 
of care. However, it was acknowledged that selected cases were amenable to attempted 
resection or debulking with low risk”[35]. It is clear that there is a role for surgery for 
the initial diagnosis, for gaining control of tumour progression, especially in those aged 
less than 5 years where secondary chemotherapy can avoid the need for radiation 
exposure [32], and for the relief of mass effect [24]. Additionally, it was stated that 
those tumours that are large, exophytic, cystic, or hypothalamic would be particularly 
amenable to surgical management [35]. 
The added benefit from the use of ioMRI for debulking of tumour has yet to be 
demonstrated. Here we present a small series of 10 patients with OPHG tumours that 
have been managed surgically at our centre, with the use of ioMRI. By utilising the 
MRIcron software package for quantitative analysis of resection volumes, a reliable 
measure of surgical outcome was possible. 7 patients proceeded to have second look 
surgery following ioMRI with further significant tumour resection taking place. We 
observed that an additional median resection volume of 27.79% took place, which 
would otherwise have been left in situ. This resulted in the comparative final remaining 
tumour volumes of 23.96% with second look surgery compared to 33.21% without 
further resection (p=0.1). Although not statistically different, a trend towards a smaller 
residual tumour volume was observed in those patients having second look surgery 
following ioMRI. 
 
More importantly, the added safety of a possible interim appraisal of the surgical goal 
and updated navigation led to no surgically related morbidity or mortality being 
observed in this series. This suggests that further, necessary resection can take place 
without any added surgically related morbidity or mortality. Although it is not clear 
from this series what the long-term benefit of further resection may be, or if there even 
is one, the impact of ioMRI on primary resection in this series allowed for on table 
evaluation of the intended surgical goals and further complication-free surgery, with 
comparable outcomes, and a trend to increased resection volumes. 
 
The role for ioMRI in tumour resection in our series of 10 OPHGs is therefore quite 
different to that which has previously been described. As the surgical aim is not 
complete resection, as this is near on impossible to perform without deficit, ioMRI 
should be used to a) assess whether the surgical goals have been completed while the 
patient is still on the table, b) provide a postoperative MRI without requiring additional 
sedation at a later date, c) assess whether further operative goals are available, necessary, 
and safe, and d) update neuronavigation, particularly in large tumours, where accuracy 
is compromised due to brainshift. 
  
This small series demonstrates a new application of ioMRI in tumour surgery. The 
complex relationship of OPHGs to neighbouring eloquent structures poses a particular 
challenge to the operating surgeon. We believe that the ability to assess and modify 
surgical goals on table, update neuronavigation, and obtain a postoperative picture 
immediately, with no added morbidity or mortality, is advantageous regardless of 
whether extra tumour is removed, because this strategy potentially allows on table 
quality and safety assessment.  
 
One of the challenges of assessing the extent to which ioMRI is responsible for greater 
tumour resection is determining the point at which the intra-operative scan is performed. 
We acknowledge that there is potentially a self-fulfilling effect when one knows that 
ioMRI is available at any point, and it is the operating surgeon who decides when to 
stop operating and perform the interim scan. Therefore, we anticipate that the 
significance of the extent of tumour resection in surgically managed OPHGs with the 
aid of ioMRI, will be better understood with a comparative study in the future. 
 
 
 
 
Conclusions: 
 
A role for the surgical management of OPHGs has been established, however these 
tumours are technically difficulty to resect due to their eloquent location, making them 
suitable for limited resection only. ioMRI allows surgical goals to be reassessed intra-
operatively following primary resection and its safety and efficacy has been previously 
established in relation to total tumour resection in the adult and paediatric population [3].  
 
Second look surgery can be performed if possible, necessary and safe to do so. We 
suggest that ioMRI may be a safe and useful addition to aid the neurosurgeon when 
performing sub-total tumour resection. We observed an additional median resection 
volume of 27.79% and final remaining tumour volume of 23.96% with second look 
surgery compared to 33.21% without further resection (p=0.1) in this case-series of 10 
OPHGs. Importantly, we did not observe any added surgically associated morbidity or 
mortality and propose that ioMRI has a useful role in this complex and delicate surgical 
area. 
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